تعداد نشریات | 20 |
تعداد شمارهها | 1,149 |
تعداد مقالات | 10,518 |
تعداد مشاهده مقاله | 45,416,044 |
تعداد دریافت فایل اصل مقاله | 11,291,718 |
Protective Effect of Edaravone Against Cyclosporine-Induced Chronic Nephropathy Through Antioxidant and Nitric Oxide Modulating Pathways in Rats | ||
Iranian Journal of Medical Sciences | ||
مقاله 7، دوره 42، شماره 2، خرداد 2017، صفحه 170-178 اصل مقاله (838.98 K) | ||
نوع مقاله: Original Article(s) | ||
نویسندگان | ||
Elahe Sattarinezhad1؛ Mohammad Reza Panjehshahin1؛ Simin Torabinezhad2؛ Eskandar Kamali-Sarvestani3؛ Shirin Farjadian4؛ Fatema Pirsalami1؛ Leila Moezi* 5 | ||
1Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran | ||
2Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran | ||
3Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran | ||
4Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran; | ||
5Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; and Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran | ||
چکیده | ||
Background: Cyclosporine A (CsA) is an immunosuppressant with therapeutic indications in various immunological diseases; however, its use is associated with chronic nephropathy. Oxidative stress has a crucial role in CsA-induced nephrotoxicity. The present study evaluates the protective effect of edaravone on CsA-induced chronic nephropathy and investigates its antioxidant and nitric oxide modulating property.Methods: Male Sprague-Dawley rats (n=66) were distributed into nine groups, including a control (group 1) (n=7). Eight groups received CsA (15 mg/kg) for 28 days while being treated. The groups were categorized as:Group 2: Vehicle (n=10)Groups 3, 4, and 5: Edaravone (1, 5, and 10 mg/kg) (n=7 each)Group 6: Diphenyliodonium chloride, a specific endothelial nitric oxide synthase (eNOS) inhibitor (n=7)Group 7: Aminoguanidine, a specific inducible nitric oxide synthase (iNOS) inhibitor (n=7)Group 8: Edaravone (10 mg/kg) plus diphenyliodonium chloride (n=7)Group 9: Edaravone (10 mg/kg) plus aminoguanidine (n=7)Blood urea nitrogen and serum creatinine levels, malondialdehyde, superoxide dismutase, and glutathione reductase enzyme activities were measured using standard kits. Renal histopathological evaluations and measurements of eNOS and iNOS gene expressions by RT-PCR were also performed. Data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey’s test (SPSS software version 18.0).Results: Edaravone (10 mg/kg) significantly attenuated CsA-induced oxidative stress, renal dysfunction, and kidney tissue injury. Aminoguanidine improved the renoprotective effect of edaravone. Edaravone reduced the elevated mRNA level of iNOS, but could not alter the level of eNOS mRNA significantly.Conclusion: Edaravone protects against CsA-induced chronic nephropathy using antioxidant property and probably through inhibiting iNOS gene expression. | ||
کلیدواژهها | ||
Edaravone؛ Nitric oxide؛ iNOS؛ eNOSe؛ Kidney diseases؛ Cyclosporine | ||
آمار تعداد مشاهده مقاله: 3,529 تعداد دریافت فایل اصل مقاله: 1,665 |